Faculty of Biology, Technion - Israel Institute of Technology, Haifa, Israel.
Safety Unit, Technion - Israel Institute of Technology, Haifa, Israel.
Clin Infect Dis. 2020 Nov 19;71(16):2073-2078. doi: 10.1093/cid/ciaa531.
The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to a current pandemic of unprecedented scale. Although diagnostic tests are fundamental to the ability to detect and respond, overwhelmed healthcare systems are already experiencing shortages of reagents associated with this test, calling for a lean immediately applicable protocol.
RNA extracts of positive samples were tested for the presence of SARS-CoV-2 using reverse transcription quantitative polymerase chain reaction, alone or in pools of different sizes (2-, 4-, 8-, 16-, 32-, and 64-sample pools) with negative samples. Transport media of additional 3 positive samples were also tested when mixed with transport media of negative samples in pools of 8.
A single positive sample can be detected in pools of up to 32 samples, using the standard kits and protocols, with an estimated false negative rate of 10%. Detection of positive samples diluted in even up to 64 samples may also be attainable, although this may require additional amplification cycles. Single positive samples can be detected when pooling either after or prior to RNA extraction.
As it uses the standard protocols, reagents, and equipment, this pooling method can be applied immediately in current clinical testing laboratories. We hope that such implementation of a pool test for coronavirus disease 2019 would allow expanding current screening capacities, thereby enabling the expansion of detection in the community, as well as in close organic groups, such as hospital departments, army units, or factory shifts.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的最近出现导致了前所未有的大规模大流行。尽管诊断测试是检测和应对的基础,但不堪重负的医疗保健系统已经面临与该测试相关的试剂短缺,因此需要立即采用精简的适用方案。
使用逆转录定量聚合酶链反应单独或在不同大小(2、4、8、16、32 和 64 个样本池)的池中将 RNA 提取物与阴性样本一起检测阳性样本中 SARS-CoV-2 的存在。当将另外 3 个阳性样本的运输介质与阴性样本的运输介质混合在 8 个样本的池时,也对其进行了测试。
使用标准试剂盒和方案,单个阳性样本可以在多达 32 个样本的池中检测到,估计假阴性率为 10%。即使在多达 64 个样本中稀释的阳性样本的检测也可能达到,但这可能需要额外的扩增循环。当在 RNA 提取后或之前进行池化时,都可以检测到单个阳性样本。
由于它使用标准的方案、试剂和设备,因此这种池化方法可以立即在当前的临床测试实验室中应用。我们希望对这种 2019 年冠状病毒疾病的池测试的实施能够扩大当前的筛查能力,从而能够在社区中进行检测,以及在医院部门、军队单位或工厂轮班等密切有机群体中进行检测。